Advances in studies on population pharmacokinetics of antiepileptic drugs and CYP450 gene polymorphisms

Abstract

Abstract: Antiepileptic drugs ( AEDs) should be used with individualized dsage regimens since they are metabolized by marked variability.It is an effective way to design individualized dosage regimens with population pharmacokinetic ( PPK) researching.There are lots of researches on PPK for antiepileptic drugs in the world, and many demographic features but genetic factors are analyzed in PPK models.CYP450 gene polymorphisms are important factors for interindividual variability.The latest advance of study for PPK is to analyze the effect on AEDs due to CYP450 gene polymorphisms, and to choose different initial doses according to gene polymorphisms.It will be valuable to facilitate individualized dosage regimen.However, one study indicates that the presently evaluated variant alleles in the CYP2C8, CYP3A4, CYP3A5 and ABCB1 genes did not explain the substantial interindividual variability in paclitaxel pharmacokinetics.Therefore,more deeply research should be done.

Key words: population pharmacokinetics, antiepileptic drugs, CYP450, gene polymorphisms

CLC Number:

R969.1

JIANG De-chun, BAI Xiang-rong, WANG Yu-qin, LI Lin. Advances in studies on population pharmacokinetics of antiepileptic drugs and CYP450 gene polymorphisms[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(11): 1207-1212.

References

1 魏树礼.药物动力学某些新进展[ A].见:魏树礼, 主编.生物药剂学与药物动力学[M].第1 版.北京:北京医科大学出版社, 2001:125
2 EL Desoky ES, Fuseau E, EL Din Amry S, Cosson V.Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients[J].EurJ Clin Pharmacol, 2004;59:783-90
3 胡敏, 张静华, 孙鹤, 施孝金, 俞丽云, 钟明康.丙戊酸群体药动学模型的建立与临床应用[J].中国医院用药评价与分析, 2001;1:95-7
4 焦正, 钟明康, 胡敏, 施孝金, 李中东, 张静华, 等.丙戊酸清除率的群体药动学模型的建立[J].中国医院药学杂志, 2004;24:515-7
5 姜德春, 王丽, 卢炜.用NONMEEM 法建立中国癫痫儿童丙戊酸钠群体药动学药效学结合模型[J].中国临床药理学与治疗学, 2005;19:1279-85
6 Romano-Moreno S, Medina-Rojas EL, Salas-Ortiz AL, Vargas-Morales JM, Perez-UrizarJT, Rodriguez-Leyva I.Population pharmacokinetics of carbamazepine in adults with epilepsy[J].Rev Invest Clin, 2005;57:38-48
7 王珏, 梁文权, 吴建军.儿童苯妥因群体药动学研究[J].浙江大学学报(医学版) , 2003;32:46-50
8 Yukawa E, Suematsu F, Yukawa M, Minemoto M.Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants[J].J Clin Pharm Ther, 2005;30:159-63
9 Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A.Lack of Chin J Clin Pharmacol Ther2006 Nov;11(11)
10 of an effect of Valproate concentration on Lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy[J].of an effect of Valproate concentration on Lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy[J].Epilepsy Res, 2000;42:23-31
11 Ingwersen SH, Pedersen PC, Groes L, Nielsen KK, Aarons L. Population pharmacokinetics of Tiagabine in epileptic patients on monotherapy[J].EurJ Pharm Sci, 2000;11:247-54
12 Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW.Population analysis of the pharmacokinetics of Tiagabine in patients with epilepsy[J].Epilepsia,1998;39:868-73
13 Ouellet D, BockbraderHN, Wesche DL, Shapiro DY, Garofalo E.Population pharmacokinetics of Gabapentin in infants and children[J].Epilepsy Res, 2001;47:229-41
14 Kelley MT,Walson PD, Cox S, Dusci LJ.Population pharmacokinetics of felbamate in children[J].TherDrug Monit, 1997;19:29-36
15 Goldstein JA.Clinical relevance of genetic polymorphisms in the human CYP2C subfamily[J].BrJ Clin Pharmacol, 2001;52:349-55
16 Anderson GD.Pharmacogenetics and enzyme induction inhibition properties of antiepileptic drugs[J].Neurology, 2004;63:S3-8
17 何楠, 周宏灏.CYP2C19 遗传多态性的研究进展[J].生理科学进展, 2003;34:171-4
18 Xie HG, Prasad HC, Kim RB, SteinMC.CYP2C9 allelic variants:ethnic distribution and functional significance [J].Adv Drug Deliv Rev, 2002;54:1257-70
19 Maekawa K, Fukushima-Uesakaa H, Tohkin M, Hasegawac R,Kajiod H, Kuzuyad N, et al.Fournovel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese[J].Pharmacogenet Genomics, 2006;16:497-514
20 Ingelman-Sundberg M, Oscarson M, McLellan RA.Polymorphic human cytochrome P450 enzymes:an opportunity forindividualized drug treatment[J].Trends Pharmacol Sci, 1999;20:342-9
21 Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, et al.Haplotypes of CYP3A4 and theirclose linkage with CYP3A5 haplotypes in a Japanese population[J].Hum Mutat, 2004;23:100
22 VanderWeide J, Steijns LS, Van Weelden MJ, De Haan K.The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement[J].Pharmacogentics, 2001;11:287-91
23 Ingelman-Sundberg M.Pharmacogenetics of cytochrome P450 and its applications in drug therapy:the past, present and future[J].Trends Pharmacol Sci, 2004;25:194-9
24 Komatsu T, Yamazaki H, Asahi S,Gillam EMJ, Guengerich FP,Nakajima M, et al.Formation of a dihydroxymetabolite of phenytoin in human livermicrosomes cytosol:roles of cytochromes P450, 2C9, 2C19 and 3A4[J].Drug Metab Dispos, 2000;28:1361-8
25 Rettie AE, Haining RL, Bajpai M, Levy RH.A common genetic basis foridiosyncratic toxicity of warfarin and phenytoin[J].Epilepsy Res, 1999;35:253-5
26 VanderWJ.Maintenance dose requirement forphenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of otherantiepileptics [J].Ned TijdschrGeneeskd, 2001;145:312-5
27 Bajpai M, Roskos LK, Shen DD, Levy RH.Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its majormetabolite[J].Drug Metab Dispos, 1996;24:1401-3
28 Yasumori T, Chen LS, Li QH, UedaM, Tsuzuki T,Goldstein JA,et al.Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese:difference in chiral preference of CYP2C9 and CYP2C19[J].Biochem Pharmacol, 1999;57:1297-303
29 Ieiri I, Mamiya K, Urae A, Wada Y, Kimura M, Irie S, et al.Stereoselective 4′-hydroxylation of phenytoin: relationshiPto (S)-mephenytoin polymorphism in Japanese[J].BrJ Clin Pharmacol,1997;43:441-5
30 黄越, 杨静芳, 齐晓涟, 王育琴, 王维治, 陈彪.CYP2C19和CYP2C9 基因型与苯妥英血药浓度关系的影响[J].中华医学杂志, 2004;84:1686-9
31 Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, et al.CYP2C19 polymorphism effect on phenobarbitone.Pharmacokinetics in Japanese patients with epilepsy analysis by population pharmacokinetics[J].EurJ Cli Pharmacol, 2000;55:821-5
32 Spina E, Arena D, Scordo MG, Fazio A, Pisani F, Perucca E.Elevation of Plasma carbamazepine by Ketoconazole in patients with Epilepsy[J].TherDrug Monit, 1997;19:535-8
33 Perucca E.Pharmacological and therapeutic properties of valproate A summary after35 years of clinical experience[J].CNS Drugs, 2002;16:695-714
34 王育琴, 齐晓涟, 黄越, 陈彪.丙戊酸药物浓度与CYP2C19 基因多态性的研究[J].中国医院药学杂志, 2003;23:670-3
35 黄越, 齐晓涟, 王育琴, 董秀敏, 陈彪, 王维治.CYP2C19基因型对丙戊酸及其与苯妥英联合用药时血药浓度影响[J].中国神经免疫学和神经病学杂, 2003;10:266-8
36 Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, et al.The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy:studies in stereoselective hydroxylation and population pharmacokinetics[J].Epilepsia, 1998;39:1317-23
37 Hung CC.Dosage recommendation of phenytoin forpatient with epilepsy with different CYP2C9 CYP2C19 polymorphisms[J].TherDrug Monit, 2004;26:534-40
38 Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A,Mross K, et al.Association of CYP2C8, CYP3A4, CYP3A5,and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel[J].Clin CancerRes, 2005;11:8097-104

[1]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[2]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[3]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[4]	YAN Yukui, HU Jianqin, ZHANG Bing. Clinical study of new and conventional antiepileptic drugs with newly diagnosed partial epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 793-799.
[5]	LIU Wei, XUE Junsheng, YU Zhiheng, WANG Ziyu, CHEN Rong, ZHOU Tianyan. Interpretation of pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 86-94.
[6]	LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian. Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
[7]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[8]	LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun. Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
[9]	GUO Xianzhong, LIN Rongfang, LIN Weiwei. Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
[10]	LI Jian, YANG Jinbo, WANG Yuzhu. Discussion on the format and content of new drug population pharmacokinetic study report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
[11]	XU Gaoqi, ZHANG Yiwen, ZHENG Xiaowei, LIU Yujia, LI Li, HUANG Ping. Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 540-545.
[12]	CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang. Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
[13]	LI Jian, YANG Jinbo, WANG Yuzhu. Applications of model-informed drug development (MIDD) on new drug research and development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 1-8.
[14]	LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping. Research progress in population pharmacokinetics of voriconazole in adults [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.
[15]	SHA Bijun, ZHOU Sufeng, WANG Lu, ZHAO Yuqing, CHEN Xijing, SHAO Feng. Methods and progress of clinical research on drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1037-1045.